Prudential PLC lessened its stake in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 3.9% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 525,317 shares of the biopharmaceutical company's stock after selling 21,204 shares during the quarter. Prudential PLC's holdings in Pfizer were worth $13,937,000 at the end of the most recent quarter.
Several other institutional investors and hedge funds have also recently made changes to their positions in the company. Retirement Wealth Solutions LLC purchased a new stake in shares of Pfizer in the 4th quarter worth approximately $26,000. Rialto Wealth Management LLC purchased a new position in shares of Pfizer in the fourth quarter worth approximately $26,000. Kohmann Bosshard Financial Services LLC purchased a new position in shares of Pfizer during the 4th quarter worth $28,000. Noble Wealth Management PBC purchased a new stake in Pfizer in the fourth quarter worth about $31,000. Finally, Curio Wealth LLC purchased a new position in Pfizer during the fourth quarter valued at approximately $32,000. Institutional investors own 68.36% of the company's stock.
Wall Street Analyst Weigh In
Several research firms recently weighed in on PFE. Hsbc Global Res raised shares of Pfizer to a "strong-buy" rating in a research note on Monday, March 10th. Bank of America restated a "neutral" rating and set a $29.00 price objective on shares of Pfizer in a research report on Tuesday, December 10th. Citigroup reiterated a "neutral" rating on shares of Pfizer in a research report on Thursday, March 27th. UBS Group cut their price target on Pfizer from $31.00 to $29.00 and set a "neutral" rating for the company in a report on Wednesday, January 8th. Finally, Truist Financial decreased their price objective on Pfizer from $36.00 to $32.00 and set a "buy" rating on the stock in a report on Wednesday, December 18th. One equities research analyst has rated the stock with a sell rating, seven have assigned a hold rating, six have given a buy rating and three have given a strong buy rating to the stock. According to MarketBeat.com, Pfizer has a consensus rating of "Moderate Buy" and a consensus price target of $31.92.
Read Our Latest Research Report on Pfizer
Insider Activity
In other Pfizer news, Director Ronald E. Blaylock acquired 19,457 shares of the stock in a transaction dated Thursday, February 13th. The stock was purchased at an average price of $25.65 per share, with a total value of $499,072.05. Following the transaction, the director now directly owns 27,707 shares of the company's stock, valued at $710,684.55. This trade represents a 235.84 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Insiders own 0.06% of the company's stock.
Pfizer Trading Down 5.4 %
Pfizer stock traded down $1.30 during midday trading on Friday, reaching $22.99. The stock had a trading volume of 79,829,399 shares, compared to its average volume of 39,460,357. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63. The company has a fifty day moving average of $25.87 and a 200 day moving average of $26.76. Pfizer Inc. has a 52-week low of $22.95 and a 52-week high of $31.54. The firm has a market cap of $130.39 billion, a price-to-earnings ratio of 16.31, a price-to-earnings-growth ratio of 0.64 and a beta of 0.67.
Pfizer (NYSE:PFE - Get Free Report) last announced its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.48 by $0.15. The firm had revenue of $17.76 billion during the quarter, compared to analyst estimates of $17.26 billion. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. Pfizer's quarterly revenue was up 24.7% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.10 earnings per share. On average, analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.
Pfizer Company Profile
(
Free Report)
Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.
Featured Stories
Before you consider Pfizer, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pfizer wasn't on the list.
While Pfizer currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
